Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

Anforth, 2012, Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, Br J Dermatol, 167, 1153, 10.1111/j.1365-2133.2012.11155.x Hwang, 2016, Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort, J Am Acad Dermatol, 74, 455, 10.1016/j.jaad.2015.10.029 Carlos, 2015, Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma, JAMA Dermatol, 151, 1103, 10.1001/jamadermatol.2015.1745 Karimkhani, 2014, A review of novel therapies for melanoma, Am J Clin Dermatol, 15, 323, 10.1007/s40257-014-0083-7 Gangadhar, 2014, Mitigating the toxic effects of anticancer immunotherapy, Nat Rev Clin Oncol, 11, 91, 10.1038/nrclinonc.2013.245 Mavropoulos, 2014, Managing the skin toxicities from new melanoma drugs, Curr Treat Options Oncol, 15, 281, 10.1007/s11864-014-0284-6 Nayar, 2016, Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma, J Immunother, 39, 149, 10.1097/CJI.0000000000000112 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Houben, 2004, Constitutive activation of the Ras–Raf signaling pathway in metastatic melanoma is associated with poor prognosis, J Carcinog, 3, 6, 10.1186/1477-3163-3-6 Dhomen, 2009, BRAF signaling and targeted therapies in melanoma, Hematol Oncol Clin North Am, 23, 529, 10.1016/j.hoc.2009.04.001 Long, 2011, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J Clin Oncol, 29, 1239, 10.1200/JCO.2010.32.4327 Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 Anforth, 2015, Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy, J Am Acad Dermatol, 72, 10.1016/j.jaad.2015.01.018 Alloo, 2012, Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma, Arch Dermatol, 148, 363, 10.1001/archdermatol.2011.3080 Fathi, 2013, A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma, Dermatol Surg, 39, 341, 10.1111/dsu.12035 Anforth, 2012, Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib, J Clin Oncol, 30, e165, 10.1200/JCO.2011.39.8594 Anforth, 2013, Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors, Br J Dermatol, 169, 1310, 10.1111/bjd.12519 Anforth, 2015, Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks, Br J Dermatol, 172, 239, 10.1111/bjd.13200 Anforth, 2013, Cutaneous toxicities of RAF inhibitors, Lancet Oncol, 14, e11, 10.1016/S1470-2045(12)70413-8 Anforth, 2012, Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors, Pigment Cell Melanoma Res, 25, 569, 10.1111/j.1755-148X.2012.01031.x Ali, 2016, Mechanisms of BRAFi induced hyperproliferative cutaneous conditions, Exp Dermatol, 25, 394, 10.1111/exd.12975 Lacouture, 2013, Analysis of dermatologic events in vemurafenib-treated patients with melanoma, Oncologist, 18, 314, 10.1634/theoncologist.2012-0333 Chu, 2012, Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study, J Am Acad Dermatol, 67, 1265, 10.1016/j.jaad.2012.04.008 Anforth, 2015, Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma, Melanoma Res, 25, 91, 10.1097/CMR.0000000000000127 Zimmer, 2012, Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, J Clin Oncol, 30, 2375, 10.1200/JCO.2011.41.1660 Dalle, 2011, Vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 365, 1448, 10.1056/NEJMc1108651 Argenziano, 2014, Dormant melanomas or changing nevi?, J Investig Dermatol, 134, 1196, 10.1038/jid.2013.512 Goppner, 2014, High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib, Acta Derm Venereol, 94, 517, 10.2340/00015555-1813 Perier-Muzet, 2014, Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy, J Investig Dermatol, 134, 1351, 10.1038/jid.2013.462 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 1694, 10.1056/NEJMoa1210093 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach, Oncologist, 18, 733, 10.1634/theoncologist.2012-0483 Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750 Brugiere, 2014, Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease, Br J Dermatol, 171, 1529, 10.1111/bjd.13300 Dummer, 2012, Ultraviolet A and photosensitivity during vemurafenib therapy, N Engl J Med, 366, 480, 10.1056/NEJMc1113752 Gelot, 2013, Vemurafenib: an unusual UVA-induced photosensitivity, Exp Dermatol, 22, 297, 10.1111/exd.12119 Menzies, 2012, Dabrafenib and its potential for the treatment of metastatic melanoma, Drug Des Dev Ther, 6, 391 Trinh, 2014, Dabrafenib therapy for advanced melanoma, Ann Pharmacother, 48, 519, 10.1177/1060028013513009 Wenk, 2013, Vemurafenib-induced DRESS, JAMA Dermatol, 149, 1242, 10.1001/jamadermatol.2013.5278 Munch, 2016, Early-onset vemurafenib-induced DRESS syndrome, Dermatology, 232, 126, 10.1159/000439272 Pattanaprichakul, 2014, Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma, J Cutan Pathol, 41, 326, 10.1111/cup.12273 Sinha, 2014, Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, Br J Dermatol, 170, 997, 10.1111/bjd.12796 Bellon, 2016, Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulphonamide compounds, Br J Dermatol, 174, 621, 10.1111/bjd.14201 Jeudy, 2015, Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis, Br J Dermatol, 172, 1454, 10.1111/bjd.13522 Lapresta, 2015, Toxic epidermal necrolysis induced by vemurafenib, Actas Dermosifiliogr, 106, 682, 10.1016/j.ad.2015.03.008 Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 371, 1877, 10.1056/NEJMoa1406037 Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 Thota, 2015, Trametinib in the treatment of melanoma, Expert Opin Biol Ther, 15, 735, 10.1517/14712598.2015.1026323 Luke, 2014, New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy, Drug Healthc Patient Saf, 6, 77, 10.2147/DHPS.S39568 Falchook, 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial, Lancet Oncol, 13, 782, 10.1016/S1470-2045(12)70269-3 Kim, 2013, Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, J Clin Oncol, 31, 482, 10.1200/JCO.2012.43.5966 Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 Anforth, 2014, Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib, Australas J Dermatol, 55, 250, 10.1111/ajd.12124 Uribe, 2014, Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy, Melanoma Res, 24, 501, 10.1097/CMR.0000000000000096 Smith, 2008, IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway, J Investig Dermatol, 128, 1286, 10.1038/sj.jid.5701155 Infante, 2012, Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial, Lancet Oncol, 13, 773, 10.1016/S1470-2045(12)70270-X Peuvrel, 2014, Dermatological toxicity associated with targeted therapies in cancer: optimal management, Am J Clin Dermatol, 15, 425, 10.1007/s40257-014-0088-2 Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 Ribas, 2014, Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study, Lancet Oncol, 15, 954, 10.1016/S1470-2045(14)70301-8 Menzies, 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma, Clin Cancer Res, 20, 2035, 10.1158/1078-0432.CCR-13-2054 Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 Alatrash, 2013, Cancer immunotherapies, their safety and toxicity, Expert Opin Drug Saf, 12, 631, 10.1517/14740338.2013.795944 Johnson, 2013, Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy, Cancer Immunol Res, 1, 373, 10.1158/2326-6066.CIR-13-0092 Callahan, 2013, Immunomodulatory therapy for melanoma: ipilimumab and beyond, Clin Dermatol, 31, 191, 10.1016/j.clindermatol.2012.08.006 Tosti, 2013, Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma, Clin Cosmet Investig Dermatol, 6, 245 Amos, 2011, Autoimmunity associated with immunotherapy of cancer, Blood, 118, 499, 10.1182/blood-2011-01-325266 Macdonald, 2015, Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways, J Am Acad Dermatol, 72, 221, 10.1016/j.jaad.2014.07.033 Wolchok, 2010, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol, 11, 155, 10.1016/S1470-2045(09)70334-1 O’Day, 2010, Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study, Ann Oncol, 21, 1712, 10.1093/annonc/mdq013 Weber, 2009, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin Cancer Res, 15, 5591, 10.1158/1078-0432.CCR-09-1024 Lemech, 2012, Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities, Clin Med Insights Oncol, 6, 53, 10.4137/CMO.S5855 Pintova, 2013, Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy, Melanoma Res, 23, 498, 10.1097/CMR.0000000000000017 Ensslin, 2013, Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis, J Am Acad Dermatol, 69, 708, 10.1016/j.jaad.2013.06.038 Assi, 2013, Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases, Curr Oncol, 20, e165, 10.3747/co.20.1265 Voskens, 2013, The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network, PLOS ONE, 8, e53745, 10.1371/journal.pone.0053745 Weber, 2015, Toxicities of immunotherapy for the practitioner, J Clin Oncol, 33, 2092, 10.1200/JCO.2014.60.0379 Tsai, 2014, PD-1 and PD-L1 antibodies for melanoma, Hum Vaccines Immunother, 10, 3111, 10.4161/21645515.2014.983409 Sanlorenzo, 2015, Pembrolizumab cutaneous adverse events and their association with disease progression, JAMA Dermatol, 151, 1206, 10.1001/jamadermatol.2015.1916 Freeman-Keller, 2016, Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes, Clin Cancer Res, 22, 886, 10.1158/1078-0432.CCR-15-1136 Pugliese, 2015, Management of dermatologic complications of lung cancer therapies, Curr Treat Options Oncol, 16, 50, 10.1007/s11864-015-0368-y Sullivan, 2015, Pembrolizumab for treatment of patients with advanced or unresectable melanoma, Clin Cancer Res, 21, 2892, 10.1158/1078-0432.CCR-14-3061 Lo, 2015, Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy, JAMA Oncol, 1, 1340, 10.1001/jamaoncol.2015.2274 Chou, 2016, Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on anti-Programmed cell Death-1 (anti-PD-1) therapy with or without ipilimumab, Am J Dermatopatholg Hwang, 2015, Time-dependent measurement of adverse events, JAMA Dermatol, 151, 1392, 10.1001/jamadermatol.2015.3579 Hwang, 2016, Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies, Melanoma Res, 26, 413, 10.1097/CMR.0000000000000260 Naidoo, 2016, Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1, Cancer Immunol Res, 4, 383, 10.1158/2326-6066.CIR-15-0123 Carlos, 2015, A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab, Melanoma Res, 25, 265, 10.1097/CMR.0000000000000155 Wakade, 2016, PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases, Melanoma Res, 26, 421, 10.1097/CMR.0000000000000263 Goldinger, 2016, Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy, Clin Cancer Res, 10.1158/1078-0432.CCR-15-2872 Matsumura, 2016, Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma, Acta Derm Venereol, 96, 259, 10.2340/00015555-2212 Kato, 2015, Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma, J Eur Acad Dermatol Venereol Sahuquillo-Torralba, 2016, Pembrolizumab: a new drug that can induce exacerbations of psoriasis, Actas Dermosifiliogr, 107, 264, 10.1016/j.ad.2015.07.012 Ohtsuka, 2015, Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma, JAMA Dermatol, 151, 797, 10.1001/jamadermatol.2015.0249 Hofmann, 2016, Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 190, 10.1016/j.ejca.2016.02.025 Camous, 2012, Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis, Curr Opin Immunol, 24, 730, 10.1016/j.coi.2012.07.010 Monfort, 2012, Vemurafenib-induced neutrophilic panniculitis, Melanoma Res, 22, 399, 10.1097/CMR.0b013e3283570792